-
Amarin Pharma, Inc. et al v. Teva Pharmaceuticals USA, Inc. et al DC
- 2:17-cv-02641
- D. Nev.
- Filed: 10/11/2017
- Closed: 05/25/2018
- Latest Docket Entry: 05/30/2018
- Judge: Miranda M. Du
+1
- PACER
2
Plaintiffs
2
Defendants
1
Accused
Product
12
Patents-in-Suit
227
Days in
Litigation
-
Amarin Pharma, Inc. et al v. Teva Pharmaceuticals USA, Inc. et al DC
- 2:17-cv-02641
- D. Nev.
- Filed: 10/11/2017
- Closed: 05/25/2018
- Latest Docket Entry: 05/30/2018
- Judge: Miranda M. Du
+1
- PACER
Cause of Action
Infringement
Assigned Judge
Outcome Summary
Patent Information
-
Validity & Enforceability
| Claim | Outcome |
|---|---|
| All challenged claims |
Enforceable and Valid
Entry 19 |
| Claim | Outcome |
|---|---|
| All challenged claims |
Enforceable and Valid
Entry 19 |
| Claim | Outcome |
|---|---|
| All challenged claims |
Enforceable and Valid
Entry 19 |
| Claim | Outcome |
|---|---|
| All challenged claims |
Enforceable and Valid
Entry 19 |
| Claim | Outcome |
|---|---|
| All challenged claims |
Enforceable and Valid
Entry 19 |
| Claim | Outcome |
|---|---|
| All challenged claims |
Enforceable and Valid
Entry 19 |
| Claim | Outcome |
|---|---|
| All challenged claims |
Enforceable and Valid
Entry 19 |
| Claim | Outcome |
|---|---|
| All challenged claims |
Enforceable and Valid
Entry 19 |
| Claim | Outcome |
|---|---|
| All challenged claims |
Enforceable and Valid
Entry 19 |
| Claim | Outcome |
|---|---|
| All challenged claims |
Enforceable and Valid
Entry 19 |
| Claim | Outcome |
|---|---|
| All challenged claims |
Enforceable and Valid
Entry 19 |
| Claim | Outcome |
|---|---|
| All challenged claims |
Enforceable and Valid
Entry 19 |
-
Infringement
Teva Pharmaceutical Industries Limited
- 12 Details
| Accused Product | Patent # | Claim # | Outcome |
|---|---|---|---|
| Generic VASCEPA 500 mg | US 8,293,728 B2 | All Asserted Claims |
Infringement
Entry 19
|
| Generic VASCEPA 500 mg | US 8,318,715 B2 | All Asserted Claims |
Infringement
Entry 19
|
| Generic VASCEPA 500 mg | US 8,357,677 B1 | All Asserted Claims |
Infringement
Entry 19
|
| Generic VASCEPA 500 mg | US 8,367,652 B2 | All Asserted Claims |
Infringement
Entry 19
|
| Generic VASCEPA 500 mg | US 8,377,920 B2 | All Asserted Claims |
Infringement
Entry 19
|
| Generic VASCEPA 500 mg | US 8,415,335 B2 | All Asserted Claims |
Infringement
Entry 19
|
| Generic VASCEPA 500 mg | US 8,426,399 B2 | All Asserted Claims |
Infringement
Entry 19
|
| Generic VASCEPA 500 mg | US 8,440,650 B1 | All Asserted Claims |
Infringement
Entry 19
|
| Generic VASCEPA 500 mg | US 8,518,929 B2 | All Asserted Claims |
Infringement
Entry 19
|
| Generic VASCEPA 500 mg | US 8,524,698 B2 | All Asserted Claims |
Infringement
Entry 19
|
| Generic VASCEPA 500 mg | US 8,546,372 B2 | All Asserted Claims |
Infringement
Entry 19
|
| Generic VASCEPA 500 mg | US 8,617,594 B2 | All Asserted Claims |
Infringement
Entry 19
|
Teva Pharmaceuticals USA, Inc.
- 12 Details
| Accused Product | Patent # | Claim # | Outcome |
|---|---|---|---|
| Generic VASCEPA 500 mg | US 8,293,728 B2 | All Asserted Claims |
Infringement
Entry 19
|
| Generic VASCEPA 500 mg | US 8,318,715 B2 | All Asserted Claims |
Infringement
Entry 19
|
| Generic VASCEPA 500 mg | US 8,357,677 B1 | All Asserted Claims |
Infringement
Entry 19
|
| Generic VASCEPA 500 mg | US 8,367,652 B2 | All Asserted Claims |
Infringement
Entry 19
|
| Generic VASCEPA 500 mg | US 8,377,920 B2 | All Asserted Claims |
Infringement
Entry 19
|
| Generic VASCEPA 500 mg | US 8,415,335 B2 | All Asserted Claims |
Infringement
Entry 19
|
| Generic VASCEPA 500 mg | US 8,426,399 B2 | All Asserted Claims |
Infringement
Entry 19
|
| Generic VASCEPA 500 mg | US 8,440,650 B1 | All Asserted Claims |
Infringement
Entry 19
|
| Generic VASCEPA 500 mg | US 8,518,929 B2 | All Asserted Claims |
Infringement
Entry 19
|
| Generic VASCEPA 500 mg | US 8,524,698 B2 | All Asserted Claims |
Infringement
Entry 19
|
| Generic VASCEPA 500 mg | US 8,546,372 B2 | All Asserted Claims |
Infringement
Entry 19
|
| Generic VASCEPA 500 mg | US 8,617,594 B2 | All Asserted Claims |
Infringement
Entry 19
|